第1章 グローバル再生医療市場 エグゼクティブサマリー
1.1. グローバル再生医療市場規模および予測（2022年～2032年）
1.2. 地域別概要
1.3. 分野別概要
1.3.1. 製品別
1.3.2. 用途別
1.3.3. エンドユーザー別
1.4. 主要トレンド
1.5. 不況の影響
1.6. アナリストの推奨事項と結論
第2章 世界の再生医療市場の定義と調査の前提条件
2.1. 調査目的
2.2. 市場の定義
2.3. 調査の前提条件
2.3.1. 対象範囲と除外範囲
2.3.2. 制限事項
2.3.3. 供給サイド分析
2.3.3.1. 供給量
2.3.3.2. インフラ
2.3.3.3. 規制環境
2.3.3.4. 市場競争
2.3.3.5. 経済的実現可能性（消費者視点
2.3.4. 需要側分析
2.3.4.1. 規制枠組み
2.3.4.2. 技術的進歩
2.3.4.3. 環境への配慮
2.3.4.4. 消費者意識と受容性
2.4. 推定方法
2.5. 調査対象年
2.6. 通貨換算レート
第3章 世界の再生医療市場のダイナミクス
3.1. 市場促進要因
3.1.1. 研究開発投資の増加
3.1.2. 遺伝子治療における技術的進歩
3.1.3. 政府支援の拡大
3.2. 市場の課題
3.2.1. 治療費の高額さ
3.2.2. 不十分な償還政策
3.3. 市場機会
3.3.1. アジア太平洋地域での拡大
3.3.2. 製品承認の増加
第4章 世界の再生医療市場の産業分析
4.1. ポーターの5つの力モデル
4.1.1. 供給業者の交渉力
4.1.2. 購入者の交渉力
4.1.3. 新規参入の脅威
4.1.4. 代替品の脅威
4.1.5. 競争の激しさ
4.2. PESTEL分析
4.2.1. 政治
4.2.2. 経済
4.2.3. 社会
4.2.4. 技術
4.2.5. 環境
4.2.6. 法律
4.3. トップ投資機会
4.4. トップ勝利戦略
4.5. 破壊的トレンド
4.6. 業界専門家による見解
4.7. アナリストの推奨事項と結論
第5章 製品別世界再生医療市場規模・予測（2022年～2032年）
5.1. セグメントダッシュボード
5.2. 世界再生医療市場：製品別収益動向分析、2022年および2032年（10億米ドル
5.2.1. 細胞療法
5.2.2. 遺伝子療法
5.2.3. 組織工学
5.2.4. 血小板濃厚製剤
第6章 再生医療の世界市場規模・予測（2022年～2032年） 用途別
6.1. セグメントダッシュボード
6.2. 再生医療の世界市場：用途別収益動向分析、2022年および2032年（単位：10億米ドル）
6.2.1. 整形外科
6.2.2. 創傷ケア
6.2.3. 腫瘍学
6.2.4. 希少疾患
6.2.5. その他
第7章 再生医療の世界市場規模・予測（2022年～2032年）エンドユーザー別
7.1. セグメントダッシュボード
7.2. 再生医療の世界市場：エンドユーザー別収益動向分析（2022年および2032年）（単位：10億米ドル）
7.2.1. 病院
7.2.2. クリニック
7.2.3. その他
第8章 地域別再生医療市場規模・予測（2022年～2032年
8.1. 北米再生医療市場
8.1.1. 米国市場規模・予測
8.1.1.1. 製品別規模・予測、2022年～2032年
8.1.1.2. 用途別内訳の規模と予測、2022年～2032年
8.1.1.3. エンドユーザー別内訳の規模と予測、2022年～2032年
8.1.2. カナダ市場の規模と予測
8.2. 欧州再生医療市場
8.2.1. 英国市場の規模と予測
8.2.2. ドイツ市場の規模と予測
8.2.3. フランス市場規模および予測
8.2.4. スペイン市場規模および予測
8.2.5. イタリア市場規模および予測
8.2.6. その他欧州市場規模および予測
8.3. アジア太平洋地域再生医療市場
8.3.1. 中国市場規模および予測
8.3.2. インド市場規模および予測
8.3.3. 日本市場規模および予測
8.3.4. オーストラリア市場規模・予測
8.3.5. 韓国市場規模・予測
8.3.6. アジア太平洋地域その他市場規模・予測
8.4. 中南米再生医療市場
8.4.1. ブラジル市場規模・予測
8.4.2. メキシコ市場規模・予測
8.4.3. 中南米その他市場規模・予測
8.5. 中東およびアフリカの再生医療市場
8.5.1. サウジアラビア市場規模および予測
8.5.2. 南アフリカ市場規模および予測
8.5.3. 中東およびアフリカのその他市場規模および予測
第9章 競合情報
9.1. 主要企業のSWOT分析
9.1.1. 企業1
9.1.2. 企業2
9.1.3. 企業3
9.2. トップ市場戦略
9.3. 企業プロフィール
9.3.1. Integra LifeSciences Corporation
9.3.1.1. 重要情報
9.3.1.2. 概要
9.3.1.3. 財務（データ入手可能性による）
9.3.1.4. 製品概要
9.3.1.5. 市場戦略
9.3.2. Bristol-Myers Squibb Company
9.3.3. Novartis AG
9.3.4. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
9.3.5. CRISPR Therapeutics
9.3.6. Stryker
9.3.7. Smith & Nephew
9.3.8. Allergan Aesthetics (AbbVie Inc.)
9.3.9. American CryoStem Corporation
9.3.10. Tegoscience
9.3.11. MIMEDX (米国)
9.3.12. Tissue Regenix (英国)
9.3.13. Kite (Gilead Sciences, Inc.) (米国)
9.3.14. AlloSource (米国)
9.3.15. bluebird bio, Inc. (米国)
第10章 研究プロセス
10.1. 研究プロセス
10.1.1. データマイニング
10.1.2. 分析
10.1.3. 市場推定
10.1.4. 検証
10.1.5. 発表
10.2. 研究属性
Regenerative medicine is an innovative field aiming to repair, replace, or regenerate damaged tissues or organs using cells, tissues, or genetic material. This technology offers the potential to treat and cure various chronic, intractable, and terminal diseases such as cancer, Parkinson's disease, Alzheimer's, diabetes, renal diseases, cardiovascular diseases, and many others. The rapid advancements in gene therapy, including the first successful in-vivo CRISPR therapy in 2021, have significantly propelled market growth. Additionally, the rising prevalence of chronic genetic disorders and increased healthcare expenditure across developed and developing nations are driving the expansion of the regenerative medicine industry.
The Global Regenerative Medicine Market is witnessing strong growth, bolstered by strategic investments and partnerships within the sector. For instance, government support for R&D is playing a pivotal role in market growth. In 2022, Washington University received a grant from the National Heart Lung and Blood Institute (NHLBI) to investigate regenerative therapies for diabetic vascular and skeletal muscle repair. Collaborations between tech and biotech firms are further accelerating advancements in the sector, as seen in the partnership between Wipro and Pandorum Technologies in 2022, which aims to integrate artificial intelligence into drug development to maximize clinical outcomes and reduce time to market.
Major players operating in the regenerative medicine market are focusing on R&D to maintain their competitive edge and to launch innovative therapies. The market is characterized by strong investment in clinical trials aimed at expanding the range of available treatments. For example, CRISPR Therapeutics' ongoing trials in gene editing therapies for cancer and rare diseases are expected to lead to new product launches, driving growth during the forecast period. However, the high cost of regenerative treatments and the lack of comprehensive reimbursement policies are key challenges that may restrain market expansion, particularly for patients requiring out-of-pocket payments for experimental therapies.
The key regions considered for the Global Regenerative Medicine Market study include Asia Pacific, North America, Europe, Latin America, Middle East & Africa, and Rest of the World. North America is a dominating region in the Global Regenerative Medicine Market in terms of revenue. The market growth in the region is being attributed to factors including advanced healthcare infrastructure, significant investments in research and development, and a high prevalence of chronic diseases. The presence of major industry players and favorable regulatory policies also contribute to the region's leading position. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising healthcare expenditure, increasing awareness of regenerative therapies, and a growing patient population with unmet medical needs are propelling rapid market growth in this region. Expanding government initiatives and collaborations in biotechnology further accelerate its growth.
Major market player included in this report are:
Integra LifeSciences Corporation (U.S.)
Bristol-Myers Squibb Company (U.S.)
Novartis AG (Switzerland)
Janssen Global Services, LLC (Belgium)
CRISPR Therapeutics (Switzerland)
Stryker (U.S.)
Smith & Nephew (U.K.)
Allergan Aesthetics (AbbVie Inc.) (U.S.)
American CryoStem Corporation (U.S.)
Tegoscience (South Korea)
MIMEDX (U.S.)
Tissue Regenix (U.K.)
Kite (Gilead Sciences, Inc.) (U.S.)
AlloSource (U.S.)
bluebird bio, Inc. (U.S.)
The detailed segments and sub-segment of the market are explained below:
By Product
Cell Therapy
Gene Therapy
Tissue Engineering
Platelet Rich Plasma
By Application
Orthopedics
Wound Care
Oncology
Rare Diseases
Others
By End User
Hospitals
Clinics
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approaches.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
Chapter 1. Global Regenerative Medicine Market Executive Summary
1.1. Global Regenerative Medicine Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Application
1.3.3. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Regenerative Medicine Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Regenerative Medicine Market Dynamics
3.1. Market Drivers
3.1.1. Increasing R&D Investments
3.1.2. Technological Advancements in Gene Therapy
3.1.3. Growing Government Support
3.2. Market Challenges
3.2.1. High Treatment Costs
3.2.2. Inadequate Reimbursement Policies
3.3. Market Opportunities
3.3.1. Expansion in Asia Pacific
3.3.2. Increasing Product Approvals
Chapter 4. Global Regenerative Medicine Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Regenerative Medicine Market Size & Forecasts by Product (2022-2032)
5.1. Segment Dashboard
5.2. Global Regenerative Medicine Market: By Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Cell Therapy
5.2.2. Gene Therapy
5.2.3. Tissue Engineering
5.2.4. Platelet Rich Plasma
Chapter 6. Global Regenerative Medicine Market Size & Forecasts by Application (2022-2032)
6.1. Segment Dashboard
6.2. Global Regenerative Medicine Market: By Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Orthopedics
6.2.2. Wound Care
6.2.3. Oncology
6.2.4. Rare Diseases
6.2.5. Others
Chapter 7. Global Regenerative Medicine Market Size & Forecasts by End User (2022-2032)
7.1. Segment Dashboard
7.2. Global Regenerative Medicine Market: By End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Hospitals
7.2.2. Clinics
7.2.3. Others
Chapter 8. Global Regenerative Medicine Market Size & Forecasts by Region (2022-2032)
8.1. North America Regenerative Medicine Market
8.1.1. U.S. Market Size & Forecast
8.1.1.1. Product breakdown size & forecasts, 2022-2032
8.1.1.2. Application breakdown size & forecasts, 2022-2032
8.1.1.3. End User breakdown size & forecasts, 2022-2032
8.1.2. Canada Market Size & Forecast
8.2. Europe Regenerative Medicine Market
8.2.1. UK Market Size & Forecast
8.2.2. Germany Market Size & Forecast
8.2.3. France Market Size & Forecast
8.2.4. Spain Market Size & Forecast
8.2.5. Italy Market Size & Forecast
8.2.6. Rest of Europe Market Size & Forecast
8.3. Asia Pacific Regenerative Medicine Market
8.3.1. China Market Size & Forecast
8.3.2. India Market Size & Forecast
8.3.3. Japan Market Size & Forecast
8.3.4. Australia Market Size & Forecast
8.3.5. South Korea Market Size & Forecast
8.3.6. Rest of Asia Pacific Market Size & Forecast
8.4. Latin America Regenerative Medicine Market
8.4.1. Brazil Market Size & Forecast
8.4.2. Mexico Market Size & Forecast
8.4.3. Rest of Latin America Market Size & Forecast
8.5. Middle East & Africa Regenerative Medicine Market
8.5.1. Saudi Arabia Market Size & Forecast
8.5.2. South Africa Market Size & Forecast
8.5.3. Rest of Middle East & Africa Market Size & Forecast
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Integra LifeSciences Corporation
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Bristol-Myers Squibb Company
9.3.3. Novartis AG
9.3.4. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
9.3.5. CRISPR Therapeutics
9.3.6. Stryker
9.3.7. Smith & Nephew
9.3.8. Allergan Aesthetics (AbbVie Inc.)
9.3.9. American CryoStem Corporation
9.3.10. Tegoscience
9.3.11. MIMEDX (U.S.)
9.3.12. Tissue Regenix (U.K.)
9.3.13. Kite (Gilead Sciences, Inc.) (U.S.)
9.3.14. AlloSource (U.S.)
9.3.15. bluebird bio, Inc. (U.S.)
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
❖ 世界の再生医療市場に関するよくある質問(FAQ) ❖
・再生医療の世界市場規模は？
→Bizwit Research & Consulting社は2023年の再生医療の世界市場規模を345.6億米ドルと推定しています。
・再生医療の世界市場予測は？
→Bizwit Research & Consulting社は2032年の再生医療の世界市場規模をXX米ドルと予測しています。
・再生医療市場の成長率は？
→Bizwit Research & Consulting社は再生医療の世界市場が2024年～2032年に年平均32.4%成長すると予測しています。
・世界の再生医療市場における主要企業は？
→Bizwit Research & Consulting社は「Integra LifeSciences Corporation (U.S.)、Bristol-Myers Squibb Company (U.S.)、Novartis AG (Switzerland)、Janssen Global Services, LLC (Belgium)、CRISPR Therapeutics (Switzerland)、Stryker (U.S.)、Smith & Nephew (U.K.)、Allergan Aesthetics (AbbVie Inc.) (U.S.)、American CryoStem Corporation (U.S.)、Tegoscience (South Korea)、MIMEDX (U.S.)、Tissue Regenix (U.K.)、Kite (Gilead Sciences, Inc.) (U.S.)、AlloSource (U.S.)、bluebird bio, Inc. (U.S.)など ...」をグローバル再生医療市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
